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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To examine psychosocial interventions in female BRCA carriers who have undergone risk-reducing surgery, and to evaluate the effec-
tiveness of such interventions on QoL and emotional well-being.
B A C K G R O U N D
Hereditary breast and ovarian cancer (HBOC) is a syndrome that
increases the risk of developing breast and ovarian cancer. It is es-
timated that up to 10% of invasive breast cancers are inherited,
most of which are associated with theBRCA1 and BRCA2 genes
(King 2003). Up to 1 in 6 (15%) of women diagnosed with ovar-
ian cancers may have an inherited pathogenic BRCA mutation.
NHS England has reported that this gene mutation accounts for
1020 of the 6800 cases of ovarian cancer diagnosed annually in
the UK (NHS England 2015). These familial breast cancer genes
have garnered attention since individuals of public interest have
revealed their personal decisions to undergo risk-reducing surgery
for breast or ovarian cancer, or both, because of a family history
of these cancers and a positive gene status (Evans 2015). Raising
the public profile of inherited breast and ovarian cancer has re-
sulted in substantial increases in referrals to cancer genetics ser-
vices throughout the UK (Evans 2015; Foster 2007; Rosenberg
2016; Watson 2004). This exposure, alongside factors that have
increased availability of genetic testing, such as Next Generation
Sequencing (NGS) and updated National Institute for Health and
Care Excellence (NICE) guidelines on genetic testing in families
with HBOC (NICE 2013), has influenced perception and uptake
of genetic testing. Prior to genetic testing for BRCA genes, which
remains themost powerful tool for determining which individuals
within a family are at risk (Euhus 2015), genetic counselling is
offered where trained genetic counsellors can facilitate testing in
a number of ways including discussion of family history, possible
test outcomes, implications of the genetic test result and risk man-
agement options (Stan 2013). Current NICE guidance sets out
the classification, care and management of familial breast cancer
and related risks in people with a family history of breast cancer
and defines those whose risk warrants a specialist genetic consul-
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tation (NICE 2013).
Description of the condition
Women who carry a pathogenic BRCAmutation are considered to
have a significantly increased cumulative lifetime risk of develop-
ing breast cancer (40% to 85%) and risk of ovarian cancer (11% to
65%) (Antoniou 2003; den Heijer 2012; Ford 1998; King 2003),
compared towomen in the general populationwhere risk for breast
and ovarian cancer is 12% and 1.3% respectively (Chen 2007).
While it is acknowledged that published estimates vary depend-
ing on study design, analyses and populations studied (Hartmann
2016), multiple other factors such as age of diagnosis of cancer in
the index family member, type of cancer, family history of cancer
and lifestyle factors contribute to this variation in risk (Mavaddat
2013). The Epidemiological Study of BRCA1 and BRCA2 muta-
tion carriers (EMBRACE), one of the largest prospective studies
collaborating with 28 centres across the UK and Ireland, discrim-
inated between the two BRCA genes. The estimated cumulative
lifetime risks, up to 70 years of age, for women with a BRCA1 mu-
tation are 60% risk of breast cancer, 59% for ovarian cancer and
83% for a contralateral breast cancer; for women with a BRCA2
mutation risks were estimated as 55% for breast cancer, 16.5% for
ovarian cancer and 62% for contralateral breast cancer (Mavaddat
2013).
Following confirmation of a pathogenic BRCA mutation women
are faced with difficult choices of how best to manage their risk
of developing breast or ovarian cancer. Options to consider are:
enhanced surveillance with magnetic resonance imaging (MRI),
mammogram and CA125 blood test, and a transvaginal ultra-
sound scan of the ovaries and fallopian tubes; risk-reducing surgery
to their breast tissue or removal of their ovaries and fallopian tubes,
or both; chemoprevention; and lifestyle interventions. A current
Cochrane protocol references the need for international guidelines
in BRCA testing in women with ovarian cancer and other can-
cers to facilitate consistent screening practices (Eleje 2016). The
United Kingdom Familial Ovarian Cancer Screening Study (UK-
FOCCS) has recently published data on screening in women who
are at high risk for ovarian and fallopian tube cancer. It concluded
that screening should not be viewed as an alternative to surgery,
but it does seem to offer a better chance of avoiding a diagnosis of
advanced incompletely resectable ovarian cancer or fallopian tube
cancer, or both, in the interim (Rosenthal 2017).
Given the high risks of breast and ovarian cancer associated with
the BRCA genes, many women choose to undergo risk-reduc-
ing mastectomy or risk-reducing bilateral salpingo-oophorectomy
(RRBSO), or both, to maximise survival (Jeffers 2014). It is re-
ported that 18% to 40% of women with a BRCA gene muta-
tion will opt for risk-reducing mastectomy (Euhus 2015), with the
higher percentage reported in the UK (Euhus 2015; Gopie 2013).
Approximately 60% of women between the ages of 35 to 70 years
who areBRCA carriers will elect to undergoRRBSO (Finch 2013).
Prospective studies report a 93% reduction in breast cancer risk for
women who undergo risk-reducing mastectomy (De Felice 2015).
Similarly, RRBSO may reduce the risk of ovarian cancer by 85%
to 90% and breast cancer risk by 40% to 70% in women who
are BRCA carriers (ACOG 2009). While such surgical interven-
tions have demonstrated increased overall survival for this popu-
lation, surgery is life-changing and can impact women adversely
at a psychological, psychosexual and emotional level (Hartmann
2016; Stan 2013). In general, women regard risk-reducing surgery
as a positive experience and have a sense of relief at the substan-
tial cancer risk reduction and improvement in survival (Metcalfe
2004). However studies have shown that, despite this positive ex-
perience, women are faced with unexpected physical changes that
affect the function and appearance of their bodies. These changes
can have a negative impact on sexuality and relationships (Gahm
2013; Gopie 2013; Hallowell 2012). The focus of this Cochrane
Review is the effectiveness of interventions on psychosocial out-
comes and survival will not be part of the scope.
Description of the intervention
Prior to genetic testing, women at risk of cancer are provided with
genetic counselling by trained genetic counsellors or consultant
geneticists, as directed by NICE guidance 164 (NICE 2013). Ge-
netic counselling, as an activity, is “the process of helping people
understand and adapt to the medical, psychological and famil-
ial implications of the genetic contributions to disease. The pro-
cess includes interpretation, risk assessment, education and coun-
selling” (Resta 2006). Specifically the role of the genetic counsel-
lor, according to Skirton 2010, is as follows.:
• To identify the needs of the individual or family and use an
empathic client-centred approach in the provision of genetic
counselling.
• To collect, select, interpret and analyse information
(including family and medical history, pedigree, laboratory
results and literature) relevant to the delivery of genetic
counselling for individuals or families.
• To help people understand and adapt to the medical,
psychological, social and familial implications of genetic
contributions to disease.
• To assess the chance of occurrence or recurrence; to provide
education about inheritance, testing, management, prevention,
resources and research to relevant individuals or families.
• To promote informed choices and psychological adaption
to the condition or risk of the condition.
• To apply expert knowledge to facilitate the individual or
family to access the appropriate healthcare resources, including a
medical diagnosis and resources for management of the
condition.
Womenwith a diagnosis of cancermay experience a different path-
way due to the recent ’mainstreaming’ of cancer genetics in some
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areas in the UK and beyond (genetic testing outside of clinical
genetics services). Women who have a diagnosis of cancer may ac-
cess genetic testing at the time of diagnosis and the pre-test coun-
selling is provided by oncologists. If a mutation is identified, these
women can be referred to genetic services for further information
and genetic counselling. Individuals who test positive for a BRCA
mutation are not routinely followed up by the genetics service
after their result disclosure consultation, but are referred on for
screening and risk-reducing consultations with surgeons.
The extent of need for psychosocial support in women who
are BRCA carriers and have undergone risk-reducing surgery has
not been wholly quantified. However, retrospective and prospec-
tive studies have highlighted women’s concerns and experiences
(Brandberg 2008; den Heijer 2012; Gahm 2010; Metcalfe 2004;
McGaughey 2006; van Oostrom 2003), with significant num-
bers of women reporting some adverse experience. Studies have
reported on long-term follow up of BRCA carriers who had risk-
reducing surgery. Studies have found that approximately one-third
of women felt less feminine, with reported changes in sexual at-
tractiveness (55%), feeling less physically attractive (53%) and
self-consciousness about appearance (53%). Other concerns were
related to surgical complications for which women received fur-
ther psychiatric intervention (Hopwood 2000). Women without
a diagnosis of cancer who underwent risk-reducing mastectomy
felt embarrassed about their naked body (21%), were not satisfied
with the appearance of reconstructed breasts (29%), but reported
significant reduction in cancer-specific distress (Gopie 2013).
This Cochrane Review will focus on psychological, psychosexual
and psychoeducational interventions provided to support female
BRCA carriers after risk-reducing surgery, and the effectiveness of
such interventions on quality of life (QoL) and the psychological
consequences of risk-reducing surgical intervention. While there
is no universal definition of QoL, it is used to describe general
health status (Aaronson 1998; Barofsky 2012). Interventions for
this review will adhere to a previous Cochrane Review’s definition
of a psychosocial intervention as non-pharmacological, involving
an interpersonal relationship between an individual, or group of
individuals, and one or more trained (usually professional) helpers
(Galway 2012).
How the intervention might work
Genetic testing and the resulting medical decisions around risk re-
duction lead to a unique set of emotional, physical and sexual issues
for women who are BRCA carriers (Matloff 2009). RRBSO results
in surgically-induced menopause, which is related to significantly
compromised sexual function (Bober 2015; Finch 2011; Robson
2003), for which there is little effective treatment. Studies have
shown that psychosocial interventions have improved women’s
sexual difficulties (Bober 2015). Improvements in overall sexual
functioning, including desire, arousal, satisfaction and pain, have
been demonstrated using interventions that integrate elements of
cognitive behavioural therapy (CBT) with sexual health education
and mindfulness meditation (Bober 2015). Similarly, mindful-
ness-based interventions in people with breast cancer have shown
improvements in QoL and stress reduction (Lengacher 2009).
Why it is important to do this review
While the literature recognises that risk-reducing procedures have
a significant impact at a psychosocial level and can affectQoL, both
at an individual level and that of the family (Brotto 2012; Finch
2013; Gopie 2013; Hallowell 2012; Jeffers 2014; Stan 2013), in-
terventions to measure such concepts and outcomes in this popu-
lation have yet to be systematically reviewed. Previous systematic
reviews and meta-analyses have assessed the efficacy of psycholog-
ical interventions in people attending sessions for sexual dysfunc-
tion (Frühauf 2013). There has been an informative literature re-
view on the influence of medical choices on QoL in unaffected
BRCA carriers (Harmsen 2015). Given the developments in ge-
netic testing and the increase in availability and uptake of test-
ing, coupled with improved surgical techniques such as breast re-
construction, more women are choosing to undergo prophylactic
bilateral mastectomy; a 12% annual increase over the last decade
has been reported in the USA (Euhus 2015). Long-term follow-
up studies on the impact of risk-reducing mastectomy have shown
that women had ongoing difficulties with body image up to two
to nine years after surgery (den Heijer 2012; Unukovych 2012).
Studies have shown that sexual side effects are the most commonly
cited areas of concern post-RRBSO for women who are BRCA
gene carriers, yet 60% of the most common symptoms women
experienced post-surgery had not been discussed before surgery
(Campfield Bonadies 2011). Women need to be provided with
information and supportive interventions to ensure they have the
best psychological outcomes following their decision to undergo
risk-reducing surgery. This review will identify the psychosocial
care and management and impact on this cohort of women pre-
and post-operatively.
O B J E C T I V E S
To examine psychosocial interventions in female BRCA carriers
who have undergone risk-reducing surgery, and to evaluate the
effectiveness of such interventions on QoL and emotional well-
being.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
Randomised controlled trials (RCTs), but these may be limited
in number due to ethical considerations and the “nature of the
clinical field” (Schouten 2016). If this is the case we will include
the following types of studies.
• Quasi-randomised trials.
• Non-randomised trials, prospective and retrospective
cohort studies.
• Interventional studies.
• Case control studies.
Types of participants
Women, 18 years or older, who have tested positive for a
pathogenic mutation in BRCA1 or BRCA2, or both. All partic-
ipants will have had risk-reducing surgery; either risk-reducing
mastectomy or RRBSO, or both. Women may or may not have
had a diagnosis of breast or ovarian cancer, or both.
Types of interventions
These will include the following.
• Psychological interventions pre or post risk-reducing
surgery, or both.
• Psychoeducational intervention pre or post risk-reducing
surgery, or both.
• Psychosexual interventions pre or post risk-reducing
surgery, or both.
We will compare any of these interventions with any other inter-
vention or usual care.
Types of outcome measures
Primary outcomes
• QoL: improved QoL assessed at specified time points
during or post-intervention, measured using a scale that has been
validated through reporting of norms in a peer-reviewed
publication such as Short Form-36 Health Survey (Ware 1998),
or the cancer generic EORTC QLQ-C30 questionnaire (Fayers
2002).
• Psychological distress: such as anxiety, depression, cancer
worry measured using a scale that has been validated through
reporting of norms in a peer-reviewed publication, such as
Impact of Event Scale (Horowitz 1979), the Beck Depression
Inventory (Beck 1974), or the General Health Questionnaire
(Goldberg 1979).
Secondary outcomes
• Sexual functioning measured using a scale that has been
validated through reporting of norms in a peer-reviewed
publication, such as the Brief Symptom Inventory (Derogatis
1983), the Female Sexual Function Index (Rosen 2000), or the
Female Sexual Distress Scale (Derogatis 2002).
• Body image measured using the Body Image Scale
(Hopwood 2001).
• Psychosocial issues to include cognitive, emotional and
spiritual.
We will include trials with different outcomes than those men-
tioned above provided they measure the same construct.
We will present a ’Summary of findings’ table and will report the
following outcomes listed in order of priority (see Data synthesis).
• Improved QoL.
• Psychological distress.
• Sexual functioning.
• Body image.
• Psychosocial well-being to include cognitive, emotional and
spiritual components.
Search methods for identification of studies
There will be no language restrictions for our searches. We will
search for papers in all languages and translate to English as nec-
essary.
Electronic searches
To identify studies for inclusion in this review, we will develop
detailed search strategies for each of the following electronic
databases.
• Cochrane Central Register of Controlled Trials
(CENTRAL, the Cochrane Library, latest issue).
• MEDLINE (Ovid 1995 to date).
• Embase (1995 to date).
• CINAHL (1995 to date).
• PsycINFO (1995 to date).
• Web of Science (1995 to date).
• Scopus (1995 to date).
The MEDLINE search strategy is presented in Appendix 1. For
databases other than MEDLINE Ovid, we will adapt the search
strategy accordingly.
Searching other resources
Unpublished and grey literature
We will search other sources such as the following.
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• USA National Cancer Institute (https://www.cancer.gov/
about-cancer/treatment/clinical-trials).
• USA National Institutes of Health (https://
clinicaltrials.gov/ct).
• ISRCTN registry (www.isrctn.com/).
• Dissertation and theses databases; British Library EThOS.
Handsearching
To try identify any unpublished studies we will handsearch the
reference lists of included studies and previous systematic reviews.
We will search conference abstracts from the following sources
from 2010 to date.
• Association of Genetic Nurse Counsellors.
• Irish Society of Human Genetics.
• Cancer Genetics Spring Meeting.
• European Society of Human Genetics.
• International Psycho Oncology Society.
• American Psycho Oncology Society.
• Gynecologic Oncology (Annual meeting of the American
Society of Gynecologic Oncologist).
• Annual Meeting of European Society of Medical Oncology
(ESMO).
• American Society of Clinical Oncology.
Data collection and analysis
Selection of studies
We will download all study titles identified by the searches into
Mendeley and remove any duplicates. Two review authors (LJ and
JR) will independently screen the keywords, titles and abstracts of
electronic citations and exclude studies that clearly do not meet
the inclusion criteria. Any disagreement will be resolved by com-
municating with all review authors. Following screening, we will
obtain full-text copies of potentially relevant references. Two re-
view authors (LJ and JR) will independently assess the eligibility
for inclusion of the retrieved citations. If differences of opinion
arise, we plan to seek the opinions of the other review authors
(DF, PM andMD). If we need additional information to ascertain
eligibility, we will contact the study authors. We will identify and
exclude duplicate reports and collate multiple reports of the same
study so that each study, rather than each report, is the unit of in-
terest in the review. We will document studies excluded after full-
text assessment, giving reasons for exclusion in the ’Characteristics
of excluded studies’ table. We will record the selection process in
sufficient detail to complete a PRISMA flow diagram.
Data extraction and management
Two review authors (LJ and JR) will independently extract data
from original reports using a data extraction form adapted for this
review available from the Cochrane Effective Practice and Organi-
sation of Care (EPOC) Group (Cochrane EPOC 2013; Appendix
2). We will resolve any disagreement by consensus between the
two review authors or, where necessary, between all review authors
(LJ, JR, DF, PM and MD).
We will use the adapted data extraction form for this review and,
where possible, extract the following information from each in-
cluded study.
• Author, year of publication and journal citation (including
language).
• Country of origin.
• Aim and inclusion criteria.
• Study design, methodology.
• Study population:
◦ the number of participants eligible;
◦ participant characteristics;
◦ age;
◦ affected or healthy at risk;
◦ type of cancer;
◦ type of risk reducing surgery;
◦ BRCA1 or BRCA2 mutation.
• Intervention details:
◦ who delivered it;
◦ duration and number of sessions;
◦ mode of delivery;
◦ content of intervention;
◦ name of validated instruments.
• Outcomes:
◦ definition of outcome;
◦ time when outcome measured e.g. one month, six
months post-surgery;
◦ unit of measurement.
• Results:
◦ the number of participants evaluated at follow-up;
◦ reasons for loss to follow-up;
◦ how each study handled missing responses if stated
and the actual results;
◦ QoL and secondary outcome measures final values and
standard deviation (SD) of outcome;
◦ record number of patients assessed at each endpoint in
the treatment arm and at follow-up to estimate the mean
difference (MD) between treatment arm and its standard error.
If we find more than one publication of the same study, we will
use the most recent publication for data extraction and collate
multiple reports of the same study as the unit of interest in the
review.
Assessment of risk of bias in included studies
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RCTs
Two review authors (LJ and JR) will independently assess the risk
of bias of each included RCT using the Cochrane ’Risk of bias’
assessment tool (Higgins 2011a).
This will include assessment of the following.
• Selection bias: this will include sequence generation and
allocation concealment.
• Performance bias: we will assess performance bias (due to
knowledge of the allocated interventions by participants and
personnel during an RCT) by assessing if study participants and
study personnel were blinded.
• Detection bias: we will assess that outcomes are assessed in a
valid way such as the use of validated instruments for
psychological measures and that they are applied to both groups.
• Attrition bias: we will assess the amount, type and handling
of incomplete data to ensure dropouts or withdrawals of
participants from studies are adequately accounted for. If less
than 20% of the data is missing on the primary outcome, we will
consider this to be low attrition bias; if 20% or more of data is
missing, we will consider it to be high attrition bias; and if we
cannot calculate the percentage of missing data, we will judge
attrition bias as unclear.
• Reporting bias: selective reporting of outcomes.
• Other possible sources of biases.
Non-randomised studies (NRS)
Two authors (LJ and JR) will assess the risk of bias of each in-
cluded NRS using the Risk of Bias in Non-randomised Studies of
Interventions (ROBINS-I) tool (Sterne 2016). For reaching ’Risk
of bias’ judgements in ROBINS-I: pre-intervention and at-inter-
vention domains see Table 1.
Measures of treatment effect
Dichotomous data
We will analyse dichotomous outcomes by calculating the risk
ratio (RR) for each included study. We will express uncertainty in
each result using 95% confidence intervals (CIs).
Continuous data
We will use mean differences if outcome measures on all studies
included in the review are made on the same scale. It is unlikely
that most psychosocial studies use the same measurement scale to
assess QoL and emotional well-being and related constructs, and
in that case we will use the standardised mean difference (SMD).
Wewill calculate effect sizes on the basis of means, SDs and sample
sizes for each study condition. We will analyse the standard error
by number of patients in the treatment arm and the number of
patients at endpoints.
Unit of analysis issues
Repeated observations on participants
If there are longitudinal designs with repeated observations on
participants, we will define several outcomes based on different
periods of follow-up and conduct separate analyses, as recom-
mended in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011a).One analysis will include all studies with
measurement at the end of intervention (post-test), and we will
base other analyses on the period of follow-up (short-term: three
months or less; medium-term: more than three to six months; and
long-term follow-up: more than six months).
Dealing with missing data
If data are missing, we will contact the study authors to request
data on outcomes.Wewill not imputemissing data for the primary
outcomes.
Assessment of heterogeneity
We expect some heterogeneity due to the clinical and method-
ological diversity. Heterogeneity between studies will be assessed
by visual inspection of forest plots, by estimation of the percentage
heterogeneity between trials which cannot be ascribed to sampling
error (I² statistic) (Higgins 2003), and by a formal statistical test
of the significance of the heterogeneity (Chi² test) (Deeks 2001),
and, if possible, by subgroup analyses. If there is no evidence of
heterogeneity, we will use a fixed-effect model, which assumes a
common underlying effect behind every trial. If there is evidence
of substantial heterogeneity, we will investigate and report the pos-
sible reasons for this. If we suspect marked heterogeneity, we will
not combine estimates. All potential causes of such heterogeneity
will be explored through subgroup and sensitivity analysis. We will
use a random-effects model if meta-analysis is appropriate; we will
assume each trial to be measuring a different, true effect. While it
is acknowledged that a random-effects model is more susceptible
to publication bias, we will incorporate methods to formally test
publication bias into the analysis as outlined below.
Assessment of reporting biases
If appropriate (i.e. if the review includes more than 10 RCTs), we
will examine funnel plots corresponding to meta-analysis of the
primary outcome to assess the potential for small study effects such
as publication bias. Additionally, we will explore possible sources
of asymmetry in funnel plot, such as selective outcome reporting,
poor methodological quality leading to spuriously inflated effects
in smaller studies, true heterogeneity, artefactual and chance as
outlined byEgger 1997. If these plots suggest that treatment effects
may not be sampled from a symmetric distribution, as assumed by
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the random-effects model, we will perform further meta-analysis
using a fixed-effect model. If the review includes fewer than 10
RCTs, thenwe will use a qualitative assessment of reporting biases,
whereby the authors will review and summarise the evidence from
the RCTs.
Data synthesis
This review will include both RCTs and NRS, if no RCTs are
available. If sufficient, clinically similar studies are available, we
will pool their results in meta-analyses using Review Manager 5
(RevMan 5) (RevMan 2014).Wewill use adjusted summary statis-
tics if available; otherwise we will use unadjusted results. Where
more than one adjusted effect is reported in a paper, we will use
the estimate that is identified as the primary adjusted effect by
study authors.
We will use random effects using invariance variance weighting
for any meta-analysis.
For continuous outcomes, we will pool the mean differences be-
tween the treatment arms at the end of follow-up if all trials mea-
sured the outcome on the same scale; otherwise we will pool the
SMD. For any dichotomous outcomes, we will calculate the RR
for each study and we will then pool these. The final discussion
will include a narrative synthesis of the findings of each study de-
sign.
Quality of the evidence
We will present the overall quality of the evidence for each out-
come (see Types of outcome measures) according to the GRADE
approach, which takes into account issues not only related to in-
ternal validity (risk of bias, inconsistency, imprecision, publica-
tion bias) but also to external validity such as directness of results
(Langendam 2013). We will create a ’Summary of findings’ table
(Appendix 3) based on themethods described the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011a), and
using GRADEpro 2015. We will use the GRADE checklist and
GRADEWorking Group quality of evidence definitions (Meader
2014).We will downgrade the evidence from ’high’ quality by one
level for serious (or by two for very serious) for each limitation.
• High quality: we are very confident that the true effect lies
close to that of the estimate of the effect.
• Moderate quality: we are moderately confident in the effect
estimate: The true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different.
• Low quality: our confidence in the effect estimate is
limited: The true effect may be substantially different from the
estimate of the effect.
• Very low quality: we have very little confidence in the effect
estimate: The true effect is likely to be substantially different
from the estimate of effect.
Subgroup analysis and investigation of heterogeneity
We will not perform post hoc subgroup analysis. Where appro-
priate, we will undertake subgroup analysis, potentially grouping
the trials by the following.
• Type of treatment regime (psychological,
psychoeducational, psychosexual intervention).
• Duration of treatment (short term less than one month,
longer term more than three months).
• Cancer diagnosis (affected women) or no cancer (healthy at
risk women).
• Type of risk-reducing surgery; mastectomy or RRBSO.
Sensitivity analysis
We will perform the following sensitivity analyses.
• Exclusion of studies that are at high risk of bias.
• Using unadjusted results.
If possible, we will conduct the analyses on an intention-to-treat
basis. If this is not possible, we will use available case analysis.
The sensitivity analysis will consider how the results would have
differed for assumed means or event rates for missing data.
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A D D I T I O N A L T A B L E S
Table 1. ’Risk of bias’ judgements in ROBINS-I: pre-intervention and at-intervention domains
Judgement Bias due to confounding Bias in selection of partici-
pants into study
Bias in classification of inter-
ventions
Low risk of bias: the study is
comparable to awell-performed
RCTwith regard to this domain
No confounding expected (i) All participants who would
have been eligible for the target
trial were included in the study;
and
(ii) for each participant, start of
follow-up and start of interven-
tion coincided
i) Intervention status is well-de-
fined; and
(ii) intervention definition is
based solely on information col-
lected at the time of interven-
tion
Moderate risk of bias: the study
is sound for a non-randomised
study with regard to this do-
main but cannot be considered
comparable to awell-performed
randomised trial
i) Confounding expected, all
known important confound-
ingdomains appropriatelymea-
sured; and
(ii) reliability and validity of
measurement of important do-
mains were sufficient, such that
we do not expect serious resid-
ual confounding
Selection into the study may
have been related to interven-
tion and outcome, but the au-
thors used appropriate methods
to adjust for the selection bias;
or
(ii) start of follow-up and start
of intervention do not coincide
for all participants; and
(a) the proportion of partici-
pants for which this was the case
was too low to induce impor-
tant bias; or
(b) the authors used appropriate
methods to adjust for the selec-
tion bias;or the review authors
are confident that the rate (haz-
ard) ratio for the effects of inter-
vention remains constant over
(i) Intervention status is well-
defined; and
(ii) some aspects of the as-
signments of intervention sta-
tus were determined retrospec-
tively
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Table 1. ’Risk of bias’ judgements in ROBINS-I: pre-intervention and at-intervention domains (Continued)
time
Serious risk of bias: the study
has some important problems
(i) At least one known impor-
tant domain was not appro-
priately measured, or not con-
trolled for; or
(ii) reliability or validity of
measurement of an important
domain was low enough that
we expect serious residual con-
founding
(i) Selection into the study was
related (but not very strongly)
to intervention and outcome,
and this could be adjusted for
in analyses; or
(ii) start of follow-up and start
of intervention do not coincide,
a potentially important amount
of follow-up time is missing
from analyses, and the rate ratio
is not constant over time
i) Intervention status is not
well-defined; or
(ii) major aspects of the as-
signments of intervention sta-
tus were determined in a way
that could have been affected by
knowledge of the outcome
Critical risk of bias: the study is
too problematic to provide any
useful evidence on the effects of
intervention
(i) Confounding inherently not
controllable; or
(ii) the use of negative con-
trols strongly suggests unmea-
sured confounding
(i) Selection into the study was
very strongly related to the in-
tervention and outcome and
this could be adjusted for in
analyses; or
(ii) a substantial amount of fol-
low-up time is likely to be miss-
ing from analyses, and
the rate ratio is not constant
over time.
Unusual: an extremely high
amount of misclassification of
intervention status, e.g. because
of unusually strong recall biases
No information on which to
base a judgement about risk of
bias for this domain
No information on whether
confounding might be present
No information is reported
about selection of participants
into the study or whether start
of follow-up and start of inter-
vention coincide
No definition of the interven-
tion or no explanation of the
source of information about in-
tervention status is reported
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. Genes, BRCA1/
2. BRCA1 Protein/
3. Genes, BRCA2/
4. BRCA2 Protein/
5. (BRCA* or brca*).mp.
6. ((BRCA* or brca*) adj5 (carrier* or tumor* or tumour* or gene* or suppress* or protein* or mutat* or alter* or damage* or inherit*
or heredit*)).mp.
7. 1 or 2 or 3 or 4 or 5 or 6
8. Prophylactic Surgical Procedures/
9. exp Mastectomy/
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10. Ovariectomy/
11. surgery.fs.
12. ((risk reduc* or prophylactic) adj5 (surg* or mastectom* or RRM or ovar* or RRBSO or BSO or bilateral salpingo-oophorectom*
or oophorectomy* or interven*)).mp.
13. 8 or 9 or 10 or 11 or 12
14. 7 and 13
15. randomized controlled trial.pt.
16. controlled clinical trial.pt.
17. randomized.ab.
18. placebo.ab.
19. randomly.ab.
20. trial.ti.
21. groups.ab.
22. exp cohort studies/
23. exp case-control studies/
24. (cohort* or prospective* or retrospective* or (case* and (control* or series))).mp.
25. 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24
26. (animals not (humans and animals)).sh.
27. 25 not 26
28. 14 and 27
Key
[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier]
Appendix 2. Data extraction form
Review title or ID
• Study ID (surname of first author and year first full report of study was published e.g. Smith 2001).
• Report IDs of other reports of this study (e.g. duplicate publications, follow-up studies).
• Notes.
General information
• Date form completed (dd/mm/yyyy).
• Name/ID of person extracting data.
• Report title (title of paper/ abstract/ report that data are extracted from).
• Report ID (if there are multiple reports of this study).
• Country of origin.
• Publication type (e.g. full report, abstract, letter).
• Study funding source (including role of funders).
• Possible conflicts of interest (for study authors).
• Notes.
Eligibility
Study characteristics
• Review inclusion criteria (insert inclusion criteria for each characteristic as defined in the protocol): Yes/No/Unclear.
• Location in text (page and paragraph/figure/table).
• Type of study.
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• Randomised trial /non-randomised trial.
• Other design (specify).
• Participants.
• Types of intervention.
• Types of outcome measures.
• Decision.
• Reason for exclusion.
• Notes.
Do not proceed if study excluded from review
Population and setting
• Description.
• Include comparative information for each group (i.e. intervention and controls) if available.
• Location in text (page and paragraph/figure/table).
• Population description (from which study participants are drawn).
• Setting (including location and social context).
• Inclusion criteria.
• Exclusion criteria.
• Method(s) of recruitment of participants.
• Notes.
Methods
• Descriptions as stated in report/paper.
• Location in text (page and paragraph/figure/table).
• Study aim.
• Design (e.g. parallel, crossover, non-RCT).
• Start date.
• End date.
• Duration of participation (from recruitment to last follow-up).
• Notes.
’Risk of bias’ assessment
See Chapter 8 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011b). Additional domains may be required
for non-randomised studies.
Domain
• Risk of bias: low/high/unclear:
◦ support for judgement;
◦ location in text (page and paragraph/figure/table);
◦ random sequence generation (selection bias).
• Allocation concealment (selection bias).
• Blinding of participants and personnel (performance bias):
◦ outcome group: all/(if required);
◦ outcome group.
• Blinding of outcome assessment (detection bias):
◦ outcome group: all/(if required);
◦ outcome group.
14Interventions to improve psychosocial well-being in female BRCA-mutation carriers following risk-reducing surgery (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• Incomplete outcome data (attrition bias).
• Selective outcome reporting? (reporting bias).
• Other bias.
• Notes.
Participants
Provide overall data and, if available, comparative data for each intervention or comparison group.
• Description as stated in report/paper.
• Location in text (page and paragraph/figure/table).
• Total number randomised (or total population at start of study for NRCTs).
• Clusters (if applicable, number, type, number people per cluster).
• Baseline imbalances.
• Withdrawals and exclusions (if not provided below by outcome).
• Age.
• Sex.
• Race/ethnicity.
• Subgroups measured.
• Cancer (Y/N).
• Type of cancer.
• Risk-reducing mastectomy.
• RRBSO.
• BRCA1 or BRCA2.
• Subgroups reported.
• Notes.
Intervention groups
(Copy and paste table for each intervention and comparison group)
• Intervention Group 1.
• Description as stated in report/paper.
• Location in text (page and paragraph/figure/table).
• Group name.
• Number randomised to group (specify whether number of people or clusters).
• Description (include sufficient detail for replication, e.g. content, dose, components; if it is a natural experiment, describe the
pre-intervention).
• Duration of treatment period.
• Timing (e.g. frequency, duration of each episode).
• Delivery (e.g. mechanism, medium, intensity, fidelity).
• Providers (e.g. number, profession, training, ethnicity etc. if relevant).
• Co-interventions.
• Notes.
Outcomes
(Copy and paste table for each outcome)
• Outcome 1.
• Description as stated in report/paper.
• Location in text (page and paragraph/figure/table).
• Outcome name.
• Time points measured (specify whether from start or end of intervention).
• Time points reported.
15Interventions to improve psychosocial well-being in female BRCA-mutation carriers following risk-reducing surgery (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• Outcome definition (with diagnostic criteria if relevant and note whether the outcome is desirable or undesirable if this is not
obvious).
• Person measuring/reporting.
• Unit of measurement (if relevant).
• Scales: upper and lower limits (indicate whether high or low score is good).
• Is outcome/tool validated? Yes/No/Unclear.
• Imputation of missing data (e.g. assumptions made for ITT analysis).
• Notes.
Results
(Copy and paste the appropriate table for each outcome, including additional tables for each time point and subgroup as required)
For randomised or non-randomised trial: dichotomous outcome
• Description as stated in report/paper.
• Location in text (page and paragraph/figure/table).
• Comparison.
• Outcome.
• Subgroup.
• Time point (specify whether from start or end of intervention).
• Note whether: post-intervention or change from baseline.
• Adjusted.
• Unadjusted.
• Intervention.
• Comparison.
• Number of events.
• Number of participants.
• Number of events.
• Number of participants.
Baseline data
• Intervention.
• Comparison
• Number of events.
• Number participants.
• Number of events.
• Number of participants.
• Number of missing participants and reasons.
• Number of participants moved from other group and reasons.
• Any other results reported.
• Unit of analysis (e.g. by individuals, health professional, practice, hospital, community).
• Statistical methods used and appropriateness of these methods (e.g. adjustment for correlation).
• Notes.
For randomised or non-randomised trial : continuous outcome
• Description as stated in report/paper:
◦ location in text (page and paragraph/figure/table);
◦ comparison;
◦ outcome;
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◦ subgroup;
◦ time point (specify whether from start or end of intervention);
◦ post-intervention or change from baseline;
◦ results;
⋄ note whether: post-intervention or change from baseline;
⋄ and whether adjusted or unadjusted;
⋄ intervention;
⋄ comparison;
⋄ mean;
⋄ SD (or other variance);
⋄ number of participants;
⋄ mean;
⋄ SD (or other variance);
⋄ number of participants.
Baseline data
• Intervention.
• Comparison.
• Mean.
• SD (or other variance).
• Number of participants.
• Mean.
• SD (or other variance).
• Number of participants.
• Number of missing participants and reasons.
• Number of participants moved from other group and reasons.
• Any other results reported.
• Unit of analysis (e.g. by individuals, health professional, practice, hospital, community).
• Statistical methods used and appropriateness of these methods (e.g. adjustment for correlation).
• Notes.
For randomised or non-randomised trial: other outcome
• Description as stated in report/paper.
• Location in text (page and paragraph/figure/table).
• Comparison.
• Outcome.
• Subgroup.
• Time point (specify whether from start or end of intervention).
• Type of outcome.
• Results:
◦ intervention result;
◦ SD (or other variance);
◦ control result;
◦ SD (or other variance);
◦ overall results;
◦ SE (or other variance);
◦ number of participants;
◦ intervention;
◦ control;
◦ number of missing participants and reasons;
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◦ number of participants moved from other group and reasons;
◦ any other results reported;
◦ unit of analysis (e.g. by individuals, health professional, practice, hospital, community);
◦ statistical methods used and appropriateness of these methods;
• Notes:
For controlled before-after study
• Description as stated in report/paper.
• Location in text (page and paragraph/figure/table).
• Comparison.
• Outcome.
• Subgroup.
• Timepoint (specify whether from start or end of intervention).
• Post-intervention or change from baseline.
• Results:
◦ intervention result;
◦ SD (or other variance);
◦ control result;
◦ SD (or other variance);
◦ overall results;
◦ SE (or other variance);
◦ No. participants;
◦ intervention;
◦ control;
◦ number of missing participants and reasons;
◦ number of participants moved from other group and reasons;
◦ any other results reported;
◦ unit of analysis (individuals, cluster/ groups or body parts);
◦ statistical methods used and appropriateness of these methods.
• Notes.
For interrupted time series or repeated measures study
• Description as stated in report/paper.
• Location in text (page and paragraph/figure/table).
• Comparison.
• Outcome.
• Subgroup.
• Length of timepoints measured (e.g. days, months).
• Total period measured.
• Number of participants measured.
• Number of missing participants and reasons.
• Number of timepoints measured.
• Pre-intervention.
• Post-intervention.
• Mean value (with variance measure).
• Difference in means (post- and pre-intervention).
• Percent relative change.
• Result reported by authors (with variance measure).
• Unit of analysis (individuals or cluster/groups).
• Statistical methods used and appropriateness of these methods.
• Notes.
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Applicability
• Does the study directly address the review question? (any issues of partial or indirect applicability): Yes/No/Unclear.
• Notes.
Other information
• Description as stated in report/paper.
• Location in text (page and paragraph/figure/table).
• Key conclusions of study authors.
• References to other relevant studies.
• Correspondence required for further study information (what and from whom).
• Further study information requested (from whom, what and when).
• Correspondence received (from whom, what and when).
• Notes
Appendix 3. Draft ’Summary of findings’ table
Interventions to improve psychosocial well-being in female BRCA-mutation carriers following risk-reducing surgery
Patient or population: adult women, 18 years or older, who have tested positive for a pathogenic mutation in BRCA1 orBRCA2, or
both and had risk-reducing surgery
Settings: outpatient
Intervention: psychosocial interventions designed to improve quality of life (QoL)
Comparison: no intervention
Outcomes Illustrative comparative risks* Relative effect
(95% CI)
Number of par-
ticipants (stud-
ies)
Quality
of the evidence
(GRADE)
Comment
Assumed risk Corresponding
risk
Improved QoL
Psychological
distress
Sexual function-
ing
Body image
Psychosocial
well-being
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk
(and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
Abbreviations: CI: confidence interval; QoL: quality of life
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(Continued)
GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: we are very uncertain about the estimate.
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